Korro Bio Statistics
Total Valuation
Korro Bio has a market cap or net worth of $161.26 million. The enterprise value is $47.36 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 14.42 million shares outstanding. The number of shares has increased by 7.42% in one year.
| Current Share Class | 14.42M |
| Shares Outstanding | 14.42M |
| Shares Change (YoY) | +7.42% |
| Shares Change (QoQ) | +23.19% |
| Owned by Insiders (%) | 4.02% |
| Owned by Institutions (%) | 43.64% |
| Float | 9.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 42.04 |
| Forward PS | n/a |
| PB Ratio | 1.35 |
| P/TBV Ratio | 1.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 12.33 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.13, with a Debt / Equity ratio of 0.36.
| Current Ratio | 8.13 |
| Quick Ratio | 7.71 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -113.83 |
Financial Efficiency
Return on equity (ROE) is -87.78% and return on invested capital (ROIC) is -29.84%.
| Return on Equity (ROE) | -87.78% |
| Return on Assets (ROA) | -26.81% |
| Return on Invested Capital (ROIC) | -29.84% |
| Return on Capital Employed (ROCE) | -49.02% |
| Weighted Average Cost of Capital (WACC) | 13.32% |
| Revenue Per Employee | $78,408 |
| Profits Per Employee | -$2.32M |
| Employee Count | 49 |
| Asset Turnover | 0.02 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $732,000 in taxes.
| Income Tax | 732,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -27.65% in the last 52 weeks. The beta is 2.23, so Korro Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.23 |
| 52-Week Price Change | -27.65% |
| 50-Day Moving Average | 12.42 |
| 200-Day Moving Average | 18.57 |
| Relative Strength Index (RSI) | 38.54 |
| Average Volume (20 Days) | 84,349 |
Short Selling Information
The latest short interest is 1.09 million, so 7.52% of the outstanding shares have been sold short.
| Short Interest | 1.09M |
| Short Previous Month | 1.06M |
| Short % of Shares Out | 7.52% |
| Short % of Float | 11.32% |
| Short Ratio (days to cover) | 5.10 |
Income Statement
In the last 12 months, Korro Bio had revenue of $3.84 million and -$113.50 million in losses. Loss per share was -$11.41.
| Revenue | 3.84M |
| Gross Profit | -45.40M |
| Operating Income | -82.76M |
| Pretax Income | -112.77M |
| Net Income | -113.50M |
| EBITDA | -79.32M |
| EBIT | -82.76M |
| Loss Per Share | -$11.41 |
Full Income StatementBalance Sheet
The company has $113.97 million in cash and $42.89 million in debt, with a net cash position of $114.17 million or $7.92 per share.
| Cash & Cash Equivalents | 113.97M |
| Total Debt | 42.89M |
| Net Cash | 114.17M |
| Net Cash Per Share | $7.92 |
| Equity (Book Value) | 119.63M |
| Book Value Per Share | 8.29 |
| Working Capital | 105.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$70.18 million and capital expenditures -$420,000, giving a free cash flow of -$70.60 million.
| Operating Cash Flow | -70.18M |
| Capital Expenditures | -420,000 |
| Depreciation & Amortization | 3.44M |
| Net Borrowing | n/a |
| Free Cash Flow | -70.60M |
| FCF Per Share | -$4.90 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -2,154.03% |
| Pretax Margin | -2,935.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.42% |
| Shareholder Yield | -7.42% |
| Earnings Yield | -70.26% |
| FCF Yield | -43.71% |
Analyst Forecast
The average price target for Korro Bio is $34.80, which is 211.23% higher than the current price. The consensus rating is "Buy".
| Price Target | $34.80 |
| Price Target Difference | 211.23% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
| Revenue Growth Forecast (5Y) | 73.87% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korro Bio has an Altman Z-Score of -2.25 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.25 |
| Piotroski F-Score | 1 |
